TrialProstate cancer and prostatic diseases2012

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

J E Ward et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.